ClinicalTrials.gg
CompletedNCT03074045Updated Jun 18, 2023

LCS16 vs. COC User Satisfaction and Tolerability Study

A Phase 3 interventional study of Levonorgestrel (Kyleena, BAY86-5028) and Ethinyl estradiol and drospirenone (Yarina, BAY86-5131) in Contraception, sponsored by Bayer. Completed at 9 sites in Russian Federation. Open to female participants aged 18 Years to 29 Years. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years to 29 Years
Sex
Female
01

Study summary

To evaluate user satisfaction in young nulliparous and parous women (18-29 years of age [inclusive]), using LCS16 compared to a COC over a period of 12 months.

02

Conditions studied

  • Contraception

Keywords

  • Intrauterine
  • Birth control
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 29 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject has signed and dated the Form (ICF).
  • The subject is healthy when requesting .
  • The subject is between 18 - 29 years of age (inclusive) at the time of signing the ICF.
  • The subject has normal or clinically insignificant cervical smear for oncocytology (i.e. Pap test) not requiring further follow up (a cervical smear has to be taken at the Screening Visit [Visit 1] or a normal result has to have been documented within the previous 6 months).
  • The subject has a history of regular (i.e., endogenous cyclicity without hormonal contraceptive use) cyclic menstrual periods (length of cycle 21 - 35 days), as confirmed by the subject.
  • The subject is willing and able to attend the scheduled study visits and to comply with the study procedures.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or current lactation (less than 6 weeks postpartum or since abortion before the Screening Visit)
  • Infected abortion or postpartum endometritis within 3 months prior to the Screening Visit.
  • Chronic, daily use of drugs that may increase serum potassium levels.
  • Undiagnosed abnormal genital bleeding.
  • Acute cervicitis or vaginitis (until successfully treated).
  • Lower urinary tract infection (until successfully treated).
  • Acute or recurrent pelvic inflammatory disease or conditions associated with increased risk for pelvic infections.
  • Congenital or acquired uterine anomaly including fibroids, in the opinion of the investigator, which would interfere with insertion and/or retention of the intrauterine system (i.e., if they distort the uterine cavity).
  • Cervical neoplasia, uterine or cervical , or sex hormone-dependent tumors.
  • History of migraine, focal migraine with asymmetrical visual loss or other symptoms indicating transient cerebral ischemia.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Test

    LCS16 (Low-dose LNG IUS)

    Drug: Levonorgestrel (Kyleena, BAY86-5028)

  • Active comparator
    Reference

    COC (Yarina)

    Drug: Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)

Interventions

  • Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years

  • DrugEthinyl estradiol and drospirenone (Yarina, BAY86-5131)

    Drug pages: Ethinyl Estradiol · Drospirenone

    COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months

06

What researchers measure

Primary outcomes

  1. Overall satisfaction rate

    5-point Likert item 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied

    Time frame: 12 months

Secondary outcomes

  1. Number of adverse events

    at 1, 6 and 12 months for all subjects during the comparative part of the study. at the end of Year 2, Year 3, Year 4 and Year 5 only for subjects, who elect to enter the LCS16 extension phase.

    Time frame: Up to 5 years

  2. Discontinuation rates

    at 1, 6 and 12 months for all subjects during the comparative part of the study. at the end of Year 2, Year 3, Year 4 and Year 5 only for subjects, who elect to enter the LCS16 extension phase.

    Time frame: Up to 5 years

  3. Bleeding pattern

    Only during the comparative part of the study

    Time frame: Up to 12 months

  4. User satisfaction and bleeding questionnaire

    At 6 and 12 months after the start of study treatment (or at early termination for those subjects discontinuing the study before completion of the 12 months) for all subjects during the comparative part of the study.

    Time frame: Up to 12 months

07

Study locations

9 sites
  • Altai State Medical University
    Barnaul, 656038, Russian Federation
  • Scientific Center of family health & human reprod. problems
    Irkutsk, 664003, Russian Federation
  • Krasnoyarsk State Medical University
    Krasnoyarsk, 660022, Russian Federation
  • City Clinical Hospital #13 Moscow
    Moscow, 115280, Russian Federation
  • LLC Reafan
    Novosibirsk, 630099, Russian Federation
  • Medical Center "Avicenna"
    Novosibirsk, 630099, Russian Federation
  • Smolensk State Medical University
    Smolensk, 214019, Russian Federation
  • LLC Medical center PRIME ROSE
    St. Petersburg, 197374, Russian Federation
  • Regional perinatal center
    Yaroslavl, 150042, Russian Federation
08

References and documents

Publications

  • Suturina L.V., Dikke G.B. Experience in the use of low-dosed levonorgestrelcontaining intrauterine system Kyleena LNG and combined oral contraceptive containing 30 mcg ethinyl estradiol and 3 mg drospirenone in young women. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2021; 11: 230-236 (in Russian)

Individual participant data

Plan to share: No — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Sep 2018, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2017
First posted
Mar 8, 2017
StartActual
Mar 13, 2017
Primary completionActual
Sep 3, 2018
CompletionActual
Aug 5, 2022
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03074045
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Mar 8, 2017
Start date
Mar 13, 2017
Primary completion
Sep 3, 2018
Completion
Aug 5, 2022
Last update
Jun 18, 2023

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levonorgestrel

Start the discussion